Curriculum Vitae

Experimental Pathology/ Unit for Hypoxia signaling in inflammation (UHSI)
Research topic(s):
Role of hypoxia inducible factors and its regulators during tumor development and inflammation
in mice.
Group leader:
Ben Wielockx, PhD
Emmy Noether group leader (DFG)
Inst. of Pathology - University of Technology Dresden
Schubertstrasse 15 - D-01307 Dresden, Germany
Tel: +49-351 4585257/ 3038 /3005
Fax: +49-351 4584328
Ben.Wielockx@uniklinikum-dresden.de
Education:
-Diploma of the first cycle, division chemistry, UGent - Belgium 1995.
-Master in sciences, division biotechnology, UGent - Belgium 1997.
-Pre-doc training in science, division biotechnology, UGent - Belgium 2001.
-Doctor of science, biotechnology (Molecular Biology), UGent - Belgium, 2002.
Training and Professional Appointments:
10/1997- 03/2002: Graduate student in the Unit of Molecular Genetics in the Mouse (Prof. Dr.
C. Libert) at the DMBR, VIB-University Ghent, Belgium.
04/2002- 07/2004: Postdoctoral fellow/Doctor-assistant at the DMBR, VIB-University Ghent,
Belgium.
08/2004-08/2007: Postdoctoral fellow at the Institute of Pathology (Prof. Dr. G. Breier),
Medizinische Fakultät Carl Gustav Carus, TU Dresden, Dresden, Germany.
From 03/2005: Laboratory animal leader (‘Tierversuchsleiter’) at the MTZ mouse facility,
Dresden, Germany.
From 09/2007: Emmy Noether Groupleader (principle investigator) at the Institute of
Pathology, Medizinische Fakultät Carl Gustav Carus, TU Dresden, Germany.
Funding:
DFG :
•Emmy Noether Nachwuchsgruppe (WI 3291/1-1) (2007-2012) Project: The role of HIF prolyl
hydroxylases in inflammation and tumor angiogenesis. (>1,2mil. €).
•SPP 1190 / Priority Programm 1190 „The Tumour-Vessel Interface“: (Ben Wielockx / Georg
Breier, Dresden project) (2009-2012) Project: HIF prolyl hydroxylases in tumor progression and
metastasis (>265.000 €).
Stand: 08.04.2011

Award:
2001: “Young investigator price” at the Matrix Metallo Proteinases Gordon Conference, Il
Ciocco, Italy, 13-18 Mai.
2001: “First price for best poster” awarded by the Dutch Society for Cell Biology during the
Belgian-Dutch Meeting on Cell Adhesion, Ghent, Belgium, 9-10 November.
2003: “Travel award” awarded by Centocor, Inc. for participating at the ‘Third Annual Meeting of
the Federation of Clinical Immunology Societies’ (FOCIS meeting, Parijs), 15-19 Mai.
2004: “MeDDrive33” awarded by the Medizinische Fakultät TUDresden for the project entitled :
“Die Bedeutung der HIF-Prolyl Hydroxylasen für Endothelzellintegrität und
Tumorangiogenese” (27.200 euro) (2005-2006).
2006: “MeDDrive38” awarded by the Medizinische Fakultät TUDresden for the project
entitled: “The role of HIF prolyl hydroxylase-2 in tumor growth and inflammation” (23.500
euro) (2007).
2007: “MeDDrive38” awarded by the Medizinische Fakultät TUDresden for the project entitled:
“The role of HIF prolyl hydroxylase-2 in inflammation using a conditional knock-out
strategy” (11.835 euro) (2008).
2008: “MeDDrive38” awarded by the Medizinische Fakultät TUDresden for the project entitled:
“Identification of the CD68:iCre mouse line in inflammation” (14.200 euro) (2009).
2009: “MeDDrive38” awarded by the Medizinische Fakultät TUDresden for the project entitled:
“The impact of CD68:iCre-PHD2f/f mice” (15.000 euro) (2010).
Group members:
Post doc : Joanna Kalucka
PhD students: Soulafa Mamlouk, Kristin Franke, Rashim Pal Singh
Technician: Antje Muschter
Internal collaborators:
David Poitz
Axel Roers
Claudia Waskow
Wieland Huttner
Gustavo Barreton
Sybille Bergmann
Georg Breier
Ronald Naumann
Francis Stewart
Konstantinos Anastassiadis
Triantafyllos Chavakis
External collaborators:
Carsten Willam, Alexander Weidemann (Erlangen)
David Greaves (Oxford, UK)
Max Gassmann (Zürich, Switzerland)
Dörthe Katschinski (Göttingen)
Stand: 08.04.2011

Christof Dame (Berlin)
Perry Maxwell, Terry Lappin (Belfast, UK)
Max Mazzone, Peter Carmeliet (Leuven, Belgium)
Participation in collaborative research projects (local, national, international):
National: SPP1190 (DFG)
Publications:
1. Libert C, Wielockx B, Hammond GL, Brouckaert P, Fiers W and Elliott RW., Identification of a locus on
distal mouse chromosome 12 that controls resistance to tumor necrosis factor-induced lethal shock.
Genomics; 55(3): 284-9, 1999. (I.F. : 3.1)
2. Libert C, Wielockx B, Grijalba B, Van Molle W, Kremmer E, Colten HR, Fiers W and Brouckaert P, The
role of complement activation in tumour necrosis factor-induced lethal hepatitis. Cytokine; 11(8): 617-
25, 1999. (I.F. : 3.3)
3. Wielockx, B., Van Molle,W., Hochepied, T., Staelens, J., and Libert, C., Detection, characterizations
and purification of a murine liver factor, capable of desensitizing towards the lethal activity of tumor
necrosis factor, Cytokine, 15:59-65, 2001. (I.F. : 3.3)
4. Wielockx, B., Bussolino F., Shapiro, S. D. and Libert, C., Involvement of a Serine Protease, But Not of
Neutrophil Elastase, in Tumor Necrosis Factor-induced Lethal Hepatitis and Induction of Plateletactivating
Factor, J. Hepatol. 35: 490-497, 2001 (I.F. : 7.8)
5. Wielockx, B., Lannoy, K., Shapiro, S. D., Itoh, T., Itohara, S., Vandekerckhove, J., and Libert, C.,
Inhibition of Matrix Metalloproteinases blocks TNF-induced Lethal Hepatitis and apoptosis, Nat. Med.
7, 1202-1208, 2001. (I.F. : 27.1)
6. Van Molle, W., Wielockx, B., Mahieu, T., Takada, M., Tanigushi, T., Sekikawa, and Libert, C. Heat
shock protects against TNF-induced lethal inflammatory shock by induction of HSP70: lessons from
hsp70 knockout mice and implications for TNF-based antitumor treatment, Immunity, 16, 685-695,
2002. (I.F. : 20.6).
7. Staelens, J., Wielockx, B., Puimège, L., Van Roy, F., Guénet, J.-L. and Libert, C. Hyporesponsiveness
of SPRET/Ei mice to tumor necrosis factor–induced lethal shock and implications for tumor necrosis
factor-based antitumor therapy, Proc. Natl. Acad. Sci. USA. 99, 9340-9345, 2002. (I.F. : 9.4).
8. Wielockx, B. and Libert, C., Serine Protease of the fibrinolysis pathway are not involved in lethal hepatitis
and fibrinogen breakdown induced by Tumor Necrosis Factor, Cytokine 21, 281-285, 2003. (I.F. : 3.3)
9. Lambert, V., Wielockx, B., Munaut, C., Galopin, C., Jost, M., Itoh, T., Werb, Z., Baker, A., Libert, C.,
Krell, H-W., Foidart, J-M., Noël, A., and Rakic, J-M., MMP-2 and MMP-9 synergize in promoting
choroidal neovascularization, FASEB J., 17 (15), 2003. (I.F. : 6.4)
10. Masson, V., Rodriguez de la Ballina L., Munaut C., Wielockx, B., Jost M. , Maillard C., Blacher S.,
Bajou K., Itoh T., Werb Z., Libert C., Foidart J. and Noël A., Impaired Malignant Keratinocyte Invasion
and Tumoral Vascularization in double MMP2 and MMP9 knock out mice, FASEB J., 19(2), 234-6,
2005. (I.F. : 6.4)
11. Wullaert, A * ., Wielockx, B.*, Van Huffel, S., Bogaert, V., De Geest, B., Papeleu, P., El Bakkouri, K.,
Heyninck, K., Libert, C., and Beyaert R., Adenoviral gene transfer of ABIN-1 protects mice from
TNF/Galactosamine-induced acute liver failure and lethality, Hepatology; 42(2), 381-9, 2005. (I.F. :
10.8) (* equally contributed).
12. Van Lint, P.*, Wielockx, B.*, Lopez-Otin, C., Noel, A., and Libert, C., MMP8-deficiency leads to
reduced development of hepatitis due to reduced LIX cleavage, J. Immunol., 175: 7642-7649,
2005. (I.F. : 5.6) (* equally contributed)
Stand: 08.04.2011

13. Van Roy, M., Wielockx, B., Baker A.. and Libert, C. The use of Tissue Inhibitors of Matrix
Metalloproteinases (TIMPs) to improve the safety of a TNF/IFNγ antitumor therapy, submitted to
Cancer Gene Therapy 14(4):372-9, 2007. (I.F. : 3.1)
14. Wielockx, B., Staelens, J., Puimège, L., Van Roy, F. and Libert, C. Description and chromosomal
mapping of the resistance against tumor necrosis factor–induced lethal shock of DBA/2 mice. J.
Immunol. 178(8):5069-75, 2007. (I.F. : 5.6)
15. Van Roy, M., Vanlaere, I., Van Lint, P., Wielockx, B., Puimége, L., Shapiro, S., Lopez-Otin, C., Wilson, C.
and Libert, C. Involvement of specific matrix metalloproteinases during TNF/IFNγ-based cancer
therapy in mice, Mol. Cancer Ther., 6(9):2563-71, 2007. (I.F.: 5.0)
16. Breier, G., Licht, AH., Nicolaus, A., Klotzsche, A., Wielockx, B., Kirsnerova, Z. HIF in vascular
development and tumour angiogenesis. Novartis Found Symp.; 283:126-33, 2007. (I.F.: 1.9)
17. Hoelscher, M, Silter, M, Krull, S, von Ahlen, M, Hesse, A, Schwartz, P, Wielockx, B, Breier, G,
Katschinski, DM, Zieseniss, A. Cardiomyocyte-specific Prolyl-4-hydroxylase domain 2 knock out protects
from acute myocardial ischaemic injury. J Biol Chem. 2011, [Epub ahead of print] (I.F.: 5.3)
18. Klotzsche-von Ameln, A., Muschter, A., Mamlouk, S., Kalucka, J., Prade, I., Franke, K., Rezaei, M.,
Poitz, D.M., Breier, G., and Wielockx, B. Inhibition of HIF Prolyl Hydroxylase-2 Blocks Tumor Growth
in Mice through the Anti-Proliferative Activity of TGF ��Cancer
Res, published 24 March 2011,
10.1158/0008-5472 (I.F.: 7.5)
Review article
19. Wielockx, B., Libert, C. and Wilson, C., Matrilysin, from cancer to inflammation and back, a
promising drug target? Cytokine Growth Factor Rev., 15(2-3), 111-5, 2004. (I.F. : 6.5)
Stand: 08.04.2011